Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor

William "Bill" Montfort, Jessica A. Wales, Andrzej Weichsel

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Significance: Soluble guanylyl/guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) and is central to the physiology of blood pressure regulation, wound healing, memory formation, and other key physiological activities. sGC is increasingly implicated in disease and is targeted by novel therapeutic compounds. The protein displays a rich evolutionary history and a fascinating signal transduction mechanism, with NO binding to an N-terminal heme-containing domain, which activates the C-terminal cyclase domains. Recent Advances: Crystal structures of individual sGC domains or their bacterial homologues coupled with small-angle x-ray scattering, electron microscopy, chemical cross-linking, and Förster resonance energy transfer measurements are yielding insight into the overall structure for sGC, which is elongated and likely quite dynamic. Transient kinetic measurements reveal a role for individual domains in lowering NO affinity for heme. New sGC stimulatory drugs are now in the clinic and appear to function through binding near or directly to the sGC heme domain, relieving inhibitory contacts with other domains. New sGC-activating drugs show promise for recovering oxidized sGC in diseases with high inflammation by replacing lost heme. Critical Issues: Despite the many recent advances, sGC regulation, NO activation, and mechanisms of drug binding remain unclear. Here, we describe the molecular evolution of sGC, new molecular models, and the linked equilibria between sGC NO binding, drug binding, and catalytic activity. Future Directions: Recent results and ongoing studies lay the foundation for a complete understanding of structure and mechanism, and they open the door for new drug discovery targeting sGC. Antioxid. Redox Signal. 26, 107-121.

Original languageEnglish (US)
Pages (from-to)107-121
Number of pages15
JournalAntioxidants and Redox Signaling
Volume26
Issue number3
DOIs
StatePublished - Jan 20 2017

Fingerprint

Guanylate Cyclase
Nitric Oxide
Chemical activation
Sensors
Heme
Pharmaceutical Preparations
Soluble Guanylyl Cyclase
Pressure regulation
Signal transduction
Blood pressure
Physiology
Energy transfer
Electron microscopy
Catalyst activity
Crystal structure

Keywords

  • coiled-coil domain
  • guanylate cyclase
  • H-NOX domain
  • hypertension
  • molecular evolution
  • stimulator compound

ASJC Scopus subject areas

  • Physiology
  • Biochemistry
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor. / Montfort, William "Bill"; Wales, Jessica A.; Weichsel, Andrzej.

In: Antioxidants and Redox Signaling, Vol. 26, No. 3, 20.01.2017, p. 107-121.

Research output: Contribution to journalReview article

@article{c1db00f800ec4592806e320548acb034,
title = "Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor",
abstract = "Significance: Soluble guanylyl/guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) and is central to the physiology of blood pressure regulation, wound healing, memory formation, and other key physiological activities. sGC is increasingly implicated in disease and is targeted by novel therapeutic compounds. The protein displays a rich evolutionary history and a fascinating signal transduction mechanism, with NO binding to an N-terminal heme-containing domain, which activates the C-terminal cyclase domains. Recent Advances: Crystal structures of individual sGC domains or their bacterial homologues coupled with small-angle x-ray scattering, electron microscopy, chemical cross-linking, and F{\"o}rster resonance energy transfer measurements are yielding insight into the overall structure for sGC, which is elongated and likely quite dynamic. Transient kinetic measurements reveal a role for individual domains in lowering NO affinity for heme. New sGC stimulatory drugs are now in the clinic and appear to function through binding near or directly to the sGC heme domain, relieving inhibitory contacts with other domains. New sGC-activating drugs show promise for recovering oxidized sGC in diseases with high inflammation by replacing lost heme. Critical Issues: Despite the many recent advances, sGC regulation, NO activation, and mechanisms of drug binding remain unclear. Here, we describe the molecular evolution of sGC, new molecular models, and the linked equilibria between sGC NO binding, drug binding, and catalytic activity. Future Directions: Recent results and ongoing studies lay the foundation for a complete understanding of structure and mechanism, and they open the door for new drug discovery targeting sGC. Antioxid. Redox Signal. 26, 107-121.",
keywords = "coiled-coil domain, guanylate cyclase, H-NOX domain, hypertension, molecular evolution, stimulator compound",
author = "Montfort, {William {"}Bill{"}} and Wales, {Jessica A.} and Andrzej Weichsel",
year = "2017",
month = "1",
day = "20",
doi = "10.1089/ars.2016.6693",
language = "English (US)",
volume = "26",
pages = "107--121",
journal = "Antioxidants and Redox Signaling",
issn = "1523-0864",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor

AU - Montfort, William "Bill"

AU - Wales, Jessica A.

AU - Weichsel, Andrzej

PY - 2017/1/20

Y1 - 2017/1/20

N2 - Significance: Soluble guanylyl/guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) and is central to the physiology of blood pressure regulation, wound healing, memory formation, and other key physiological activities. sGC is increasingly implicated in disease and is targeted by novel therapeutic compounds. The protein displays a rich evolutionary history and a fascinating signal transduction mechanism, with NO binding to an N-terminal heme-containing domain, which activates the C-terminal cyclase domains. Recent Advances: Crystal structures of individual sGC domains or their bacterial homologues coupled with small-angle x-ray scattering, electron microscopy, chemical cross-linking, and Förster resonance energy transfer measurements are yielding insight into the overall structure for sGC, which is elongated and likely quite dynamic. Transient kinetic measurements reveal a role for individual domains in lowering NO affinity for heme. New sGC stimulatory drugs are now in the clinic and appear to function through binding near or directly to the sGC heme domain, relieving inhibitory contacts with other domains. New sGC-activating drugs show promise for recovering oxidized sGC in diseases with high inflammation by replacing lost heme. Critical Issues: Despite the many recent advances, sGC regulation, NO activation, and mechanisms of drug binding remain unclear. Here, we describe the molecular evolution of sGC, new molecular models, and the linked equilibria between sGC NO binding, drug binding, and catalytic activity. Future Directions: Recent results and ongoing studies lay the foundation for a complete understanding of structure and mechanism, and they open the door for new drug discovery targeting sGC. Antioxid. Redox Signal. 26, 107-121.

AB - Significance: Soluble guanylyl/guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) and is central to the physiology of blood pressure regulation, wound healing, memory formation, and other key physiological activities. sGC is increasingly implicated in disease and is targeted by novel therapeutic compounds. The protein displays a rich evolutionary history and a fascinating signal transduction mechanism, with NO binding to an N-terminal heme-containing domain, which activates the C-terminal cyclase domains. Recent Advances: Crystal structures of individual sGC domains or their bacterial homologues coupled with small-angle x-ray scattering, electron microscopy, chemical cross-linking, and Förster resonance energy transfer measurements are yielding insight into the overall structure for sGC, which is elongated and likely quite dynamic. Transient kinetic measurements reveal a role for individual domains in lowering NO affinity for heme. New sGC stimulatory drugs are now in the clinic and appear to function through binding near or directly to the sGC heme domain, relieving inhibitory contacts with other domains. New sGC-activating drugs show promise for recovering oxidized sGC in diseases with high inflammation by replacing lost heme. Critical Issues: Despite the many recent advances, sGC regulation, NO activation, and mechanisms of drug binding remain unclear. Here, we describe the molecular evolution of sGC, new molecular models, and the linked equilibria between sGC NO binding, drug binding, and catalytic activity. Future Directions: Recent results and ongoing studies lay the foundation for a complete understanding of structure and mechanism, and they open the door for new drug discovery targeting sGC. Antioxid. Redox Signal. 26, 107-121.

KW - coiled-coil domain

KW - guanylate cyclase

KW - H-NOX domain

KW - hypertension

KW - molecular evolution

KW - stimulator compound

UR - http://www.scopus.com/inward/record.url?scp=85009400062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009400062&partnerID=8YFLogxK

U2 - 10.1089/ars.2016.6693

DO - 10.1089/ars.2016.6693

M3 - Review article

C2 - 26979942

AN - SCOPUS:85009400062

VL - 26

SP - 107

EP - 121

JO - Antioxidants and Redox Signaling

JF - Antioxidants and Redox Signaling

SN - 1523-0864

IS - 3

ER -